Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AG 1295 是选择性血小板衍生生长因子受体酪氨酸激酶抑制剂。它能抑制 PDGFR 的自磷酸化,对 EGF 受体的自磷酸化无影响。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 218 | 现货 | ||
5 mg | ¥ 495 | 现货 | ||
10 mg | ¥ 828 | 现货 | ||
25 mg | ¥ 1,470 | 现货 | ||
50 mg | ¥ 2,490 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 现货 |
产品描述 | AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4]. |
体外活性 | AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro[2]. AG 1295 inhibits PDGFR autophosphorylation with IC50s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively[1]. |
体内活性 | AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibition of PDGFR-beta-triggered tyrosine phosphorylation[3]. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly reduces interstitial fibrosis as verified by a smaller Sirius-Red stained area, and by a reduced number of macrophages, and by the ED-A+ fibronectin deposition. It is also verified by the number of cells positive for alpha-smooth muscle actin[4]. |
分子量 | 234.3 |
分子式 | C16H14N2 |
CAS No. | 71897-07-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (256.08 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.268 mL | 21.3402 mL | 42.6803 mL | 106.7008 mL |
5 mM | 0.8536 mL | 4.268 mL | 8.5361 mL | 21.3402 mL | |
10 mM | 0.4268 mL | 2.134 mL | 4.268 mL | 10.6701 mL | |
20 mM | 0.2134 mL | 1.067 mL | 2.134 mL | 5.335 mL | |
50 mM | 0.0854 mL | 0.4268 mL | 0.8536 mL | 2.134 mL | |
100 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 1.067 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AG 1295 71897-07-9 Angiogenesis Tyrosine Kinase/Adaptors PDGFR Platelet-derived growth factor receptor RTK AG-1295 inhibit PDGF-receptor autophosphorylation Inhibitor AG1295 inhibitor